ERBB2 and breast carcinoma: Even though a driver mutation of the RAS signaling pathway, oncogenic K-RAS, is present in only 5% of breast cancer patients, the EGFR/HER2/K-RAS pathway is active in a large percentage of locally advanced, chemo-resistant, relapsed, and metastatic mammary tumors [71,72].